TIRZEPATIDE · DECODED
Tirzepatide
Decoded · Eli Lilly · FDA Approved
BY THE NUMBERS
HOW IT WORKS
Dual agonist at GLP-1 and GIP receptors. GLP-1 suppresses appetite and slows gastric emptying; GIP amplifies glucose-dependent insulin response and improves lipid metabolism. The combined receptor activation produces additive effects not achievable from GLP-1 agonism alone, which is why tirzepatide outperformed semaglutide head-to-head in SURMOUNT-5.
WHERE IT CAME FROM
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist developed by Eli Lilly. The technical name describes the mechanism precisely: it is a single molecule that activates two separate hormone receptors, GIP and GLP-1, simultaneously. GIP was long considered the lesser partner in the incretin system, a hormone that released insulin after eating but appeared to have little metabolic significance on its own. Tirzepatide changed that read.
The addition of GIP agonism appears to work synergistically with GLP-1. GIP receptors in fat tissue may increase how efficiently fat is burned for energy. GIP also reduces some of the nausea that GLP-1 receptor activation alone produces, which helps patients tolerate higher doses. The result is a molecule that achieves substantially more weight loss than any prior approved GLP-1 receptor agonist, with a side effect profile that is generally comparable. Eli Lilly received FDA approval for tirzepatide under the brand name Mounjaro for type 2 diabetes in May 2022, and under the brand name Zepbound for chronic weight management in November 2023.
THE STUDIES
WHAT THE STUDIES SHOW
WEIGHT LOSS
- ▸22.5% avg weight loss (SURMOUNT-1, 72 wk)
- ▸63% of patients lost ≥20% body weight at 15 mg
- ▸Outperforms semaglutide in the first direct head-to-head trial (SURMOUNT-5, NEJM 2025)
- ▸Weight regain occurs after stopping
CARDIOMETABOLIC
- ▸Blood sugar (HbA1c) reduction up to 2.46% in Type 2 Diabetes (SURPASS-2)
- ▸Significant triglyceride and LDL reduction
- ▸Systolic blood pressure reduction
- ▸Insulin sensitivity improvement
BEYOND WEIGHT
- ▸55% reduction in sleep apnea events (no CPAP group)
- ▸Metabolic liver disease (MASH) benefit in early data
- ▸Cardiovascular outcomes trial ongoing
- ▸Kidney disease signals under investigation
SIDE EFFECTS
COMMON (TITRATION PHASE)
- ▸Nausea (~30% at therapeutic doses)
- ▸Diarrhea (~20%)
- ▸Vomiting and constipation
- ▸Decreased appetite, abdominal discomfort
- ▸GIP co-agonism reduces nausea versus GLP-1 alone
NOTABLE / LESS COMMON
- ▸Gallbladder disease, including cholecystitis
- ▸Pancreatitis (rare, monitor for symptoms)
- ▸Thyroid C-cell tumors in rodent studies (human relevance unknown)
- ▸Injection site reactions
- ▸Hypoglycemia risk when combined with insulin or sulfonylureas
REGULATORY STATUS
Tirzepatide holds two FDA approvals under separate brand names for separate indications. Mounjaro is approved for glycemic control in adults with type 2 diabetes. Zepbound is approved for chronic weight management in adults with a body mass index of 30 or greater, or 27 or greater with at least one weight-related condition such as hypertension, type 2 diabetes, or obstructive sleep apnea. The sleep apnea indication was added in 2024 based on SURMOUNT-OSA data, making Zepbound the first FDA-approved pharmacotherapy for that condition. Compounded tirzepatide was available through 503A and 503B facilities during documented shortage periods, with compounding eligibility shifting as brand supply stabilized through 2024 and 2025.
PROS & CONS
PROS
- +Highest measured weight loss of any FDA-approved drug in this class
- +Dual mechanism reduces GI side effects compared to GLP-1 alone at equivalent doses
- +Approved for sleep apnea, expanding the clinical case for coverage
- +Consistently outperforms semaglutide in head-to-head trial data
- +Once-weekly injection
- +Broad and growing insurance coverage as indications expand
CONS
- −Not yet matched by a cardiovascular outcomes trial result equivalent to SELECT
- −Weight regain is significant after stopping
- −Gallbladder and thyroid monitoring required
- −List price high without insurance
- −Compounding availability has narrowed as shortage status has shifted
- −Long-term data still accumulating, approved only since 2022
DAILY PEPTIDE VERDICT
RANKING
Tirzepatide is the most effective FDA-approved weight loss drug by Phase 3 data. The SURMOUNT-1 figures — 22.5% average body weight loss, 63% of patients losing at least 20% — are not incremental improvements on prior drugs. They represent a category shift. The dual GIP and GLP-1 mechanism appears genuinely synergistic: more weight loss, comparable tolerability, and a broader emerging evidence base across sleep apnea, cardiovascular outcomes, and metabolic liver disease. The one area where semaglutide holds more data is cardiovascular outcomes, where SELECT established a 20% reduction in major cardiac events. Tirzepatide's equivalent outcomes trial is still enrolling. Within the FDA-approved class, tirzepatide currently shows the highest Phase 3 weight loss data and the most expansive indication set. Retatrutide is not yet approved and will be the relevant comparison once it is.
DISCLAIMER · EDUCATIONAL USE ONLY
This document is for educational and informational purposes only. Tirzepatide is an FDA-approved pharmaceutical. Prescribing, dosing, and clinical application are the purview of a licensed healthcare provider. Information here synthesizes publicly available clinical data and does not constitute medical advice.